Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 11,393 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: recombinant interferon alfa, recombinant interleukin-12; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes
Interventions: StemEx®; Drug
Lead sponsor: Gamida Cell -Teva Joint Venture Ltd.; Other
Eligibility: 12 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 16
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 10 more

Conditions: HIV/AIDS
Interventions: Not listed
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older
Enrollment: 818 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2025
U.S. locations: 13
States / cities: La Jolla, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more

Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Interventions: No Intervention; Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2035
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Opioid Use Disorder
Interventions: Brenipatide, Placebo, Buprenorphine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 46
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 35 more

Conditions: Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions: OPC-108459, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Hollywood, Florida • Jacksonville, Florida + 6 more

Conditions: Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
Interventions: Pegylated Irinotecan; Drug
Lead sponsor: Joel Neal; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Plantar Fasciitis
Interventions: Treatment Cohort, Control Cohort; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Endometrial Cancer
Interventions: OK-1 & Paclitaxel; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Rebastinib, Paclitaxel, Eribulin Mesylate; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lumbar Radiculopathy, Lesion of Sciatic Nerve, Left Lower Limb, Lesion of Sciatic Nerve, Right Lower Limb, Lumbar Spinal Stenosis, Lumbar Spondylosis, Lumbago With Sciatica, Left Side, Lumbago With Sciatica, Right Side
Interventions: Osteopathic Manipulative Treatment (OMT); Procedure
Lead sponsor: Rowan University; Other
Eligibility: 18 Years to 84 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: East Lansing, Michigan • Stratford, New Jersey • Voorhees Township, New Jersey

Conditions: Major Bleeding
Interventions: None (Observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 25
States / cities: Chandler, Arizona • Orange, California • Sacramento, California + 22 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Tisagenlecleucel; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Gonorrhea, Chlamydia, Meningococcal Vaccines
Interventions: Trumenba Vaccine, MenACWY Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Years to 30 Years
Enrollment: 1,307,378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: SCN2A Encephalopathy, SCN8A Encephalopathy
Interventions: PRAX-562; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 1 more

Conditions: HIV Infections
Interventions: Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more

Conditions: Age-Related Macular Degeneration, Neovascularization, Choroidal
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 50 Years and older
Enrollment: 73 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neoplasms
Interventions: BXQ-350; Drug
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Lexington, Kentucky • Albuquerque, New Mexico • Cincinnati, Ohio + 1 more

Conditions: Chronic Pain, Nociceptive Pain, Pain
Interventions: CNTX-6016, Other: Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Prostate Cancer
Interventions: Lycopene, Multivitamin, Soy isoflavones; Dietary Supplement
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 5
States / cities: Phoenix, Arizona • Tampa, Florida • Savannah, Georgia + 2 more

Conditions: Crohn Disease
Interventions: Interleukin-2 (aldesleukin).; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Healthy Volunteer
Interventions: Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCl Intravenous (IV) Injection, Treatment D: Naloxone HCl Intramuscular (IM) Injection; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Injury
Interventions: Not listed
Lead sponsor: Poudre Valley Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Loveland, Colorado

Conditions: Healthy Volunteer, Older Adults (65-85 Years)
Interventions: Psilocybin (Usona Institute); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Search by objective public record fields.

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

A Study of Brenipatide in Participants With Opioid Use Disorder

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

The Effects of Terrain Variation on Intrinsic Foot Musculature in Healthy Individuals and Individuals With Plantar Fasciitis

Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Cost Effectiveness of OMT for Chronic Low Back Pain

A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

Impact of Non-Exudative Type 1 MNV on AMD Progression

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy

Low Dose IL-2 for the Treatment of Crohn's Disease

A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers

Serum Vasopressin Levels and Severe Hemorrhagic Shock

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults